NYSEAMERICAN:PLXProtalix Biotherapeutics Stock Price, Forecast & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protalix Biotherapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Protalix Biotherapeutics.

Protalix Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Protalix Biotherapeutics.

Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) posted its earnings results on Monday, June, 1st. The company reported $0.10 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.30) by $0.40. The business had revenue of $21.65 million for the quarter, compared to analysts' expectations of $6.60 million. During the same period last year, the firm posted ($0.50) earnings per share. View Protalix Biotherapeutics' earnings history.

Protalix Biotherapeutics's stock reverse split on the morning of Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 19th 2019. An investor that had 100 shares of Protalix Biotherapeutics stock prior to the reverse split would have 10 shares after the split.

Press coverage about PLX stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Protalix Biotherapeutics earned a news sentiment score of 1.7 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the next few days. View the latest news aboutProtalix Biotherapeutics.

Protalix Biotherapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 1,260,000 shares, an increase of 13.5% from the April 30th total of 1,110,000 shares. Based on an average daily volume of 179,500 shares, the short-interest ratio is presently 7.0 days. Approximately 11.2% of the company's shares are sold short. View Protalix Biotherapeutics' Current Options Chain.

Some companies that are related to Protalix Biotherapeutics include Antibe Therapeutics (ATE), Ergomed (ERGO), Theratechnologies (TH), Rafael (RFL), Pfenex (PFNX), OncoCyte (OCX), Neuren Pharmaceuticals (NEU), IMV (IMV), Horizon Discovery Group (HZD), Faron Pharmaceuticals Oy (FARN), BiomX (PHGE), OncoCyte (OCX), Resverlogix (RVX), Tiziana Life Sciences (TILS) and Orgenesis (ORGS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Protalix Biotherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Pluristem Therapeutics (PSTI), Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL), VBI Vaccines (VBIV), Amarin (AMRN), BIOLINERX LTD/S (BLRX) and Nabriva Therapeutics (NBRV).

Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."

Protalix Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Jane Street Group LLC (0.34%). View institutional ownership trends for Protalix Biotherapeutics.

PLX stock was bought by a variety of institutional investors in the last quarter, including Jane Street Group LLC. View insider buying and selling activity for Protalix Biotherapeutics.

Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PLX stock can currently be purchased for approximately $3.37.

Protalix Biotherapeutics has a market capitalization of $109.33 million. Protalix Biotherapeutics employs 184 workers across the globe.

The official website for Protalix Biotherapeutics is www.protalix.com.

Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100.